Biotechnology
Parabilis Medicines raised $670 million in the largest-ever venture-backed biotech IPO, breaking Moderna's eight-year record. We examine what the company's novel Helicon peptide platform and the market's appetite for it reveal about where drug discovery is heading.
Biotechnology
GSK's $10.6 billion acquisition of Nuvalent Bio secures two near-approval precision oncology drugs for NSCLC and signals a broader strategic shift toward building a lung cancer franchise. We examine what the deal reveals about where targeted therapy is heading.
Biotechnology
Johnson and Johnson's $1 billion acquisition of Firefly Bio signals a major shift in cancer drug design. We explore what degrader antibody conjugates mean for the future of oncology and why this bet matters for patients with KRAS-driven cancers.
Pharmaceuticals
Data from Boehringer Ingelheim's survodutide Phase 3 trials reveals a mechanistically distinct approach to obesity treatment, with exceptional reductions in visceral and liver fat that reframe what obesity drugs can achieve.
Biotechnology
ADC Therapeutics' LOTIS-5 trial showed three times as many deaths in the Zynlonta arm versus controls. The result raises important questions about the accelerated approval pathway and the ADC field's limits.
Policy
When Eli Lilly announced it was cutting its planned German investment in half, the news landed with the weight of a verdict. Together with Boehringer Ingelheim's cancellation of 900 million euros in spending, more than $2 billion in future investment was pulled from Germany in a single day.
Biotechnology
For the first time in clinical oncology history, daraxonrasib has extended median overall survival past one year in previously treated metastatic pancreatic cancer—a breakthrough that rewrites what medicine can offer in one of oncology's most resistant diseases.
Biotechnology
At ASCO 2026, two competing KIT inhibitor programs delivered data that together signal the end of a twenty-year therapeutic standstill in gastrointestinal stromal tumors.
Pharmaceuticals
Pfizer's $10.5 billion deal with China's Innovent Biologics signals a major strategic shift in how Western pharma is leveraging Chinese biotech innovation in oncology.
Get our in depth reports sent directly to your inbox. Unsubscribe anytime.
GSK's bepirovirsen achieves functional cure in nearly one in five hepatitis B patients—a breakthrough after sixty years of managing the disease without curing it.
Eli Lilly is making a $4 billion commitment to rebuild its infectious disease portfolio from scratch, acquiring three vaccine developers and signaling a strategic pivot away from its GLP-1 dominance.
Eli Lilly's VERVE-102 data show a single infusion can permanently reduce LDL cholesterol by 50-70%, potentially transforming cardiovascular disease management and solving the adherence problem that has plagued statins for decades.
The FDA's accelerated approval of Gilead's Hepcludex marks the first-ever US treatment for hepatitis delta virus, ending decades of therapeutic neglect for one of the most severe forms of viral hepatitis.
Merck and Kelun's sacituzumab tirumotecan combined with pembrolizumab shows a 65% improvement in progression-free survival versus Keytruda monotherapy in first-line NSCLC, marking a potential paradigm shift in lung cancer treatment.
The WHO has declared the Bundibugyo Ebola outbreak a global health emergency. With no approved treatments, the US government has turned to a small San Diego biotech and its experimental antibody MBP134. The story reveals a structural gap in how the world prepares for infectious disease.
Most people at this point have heard of Ozempic. Far fewer have heard of the patients it does not help. For a meaningful subset of obese patients, GLP-1 drugs simply do not work, because the appetite circuit in their brain is broken in a way GLP-1 mechanisms cannot
AstraZeneca's Baxfendy (baxdrostat) is the first aldosterone synthase inhibitor approved by the FDA, offering a fundamentally new approach to treating resistant hypertension in the 23 million Americans whose blood pressure remains uncontrolled despite multiple medications.
Three competing technologies—from Sanofi, Wave Life Sciences, and Beam Therapeutics—are finally challenging Alpha-1 Antitrypsin Deficiency after four decades of limited treatment options.
MediWound Ltd. (Nasdaq: MDWD) recently earned a spot in one of Europe's most exclusive health security forums, and the timing could not be more relevant.
Regeneron's Phase 3 HARMONY trial of fianlimab plus cemiplimab missed statistical significance in melanoma despite a 5.1-month PFS improvement. What the p-value of 0.0627 reveals about dual checkpoint blockade.
AstraZeneca's VOLGA Phase 3 trial delivers a statistically significant overall survival benefit for cisplatin-ineligible muscle-invasive bladder cancer patients, marking a turning point for a population that has long been underserved by perioperative treatment options.
